<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>156777</routedMedId>
		<routedMedName>Zelboraf</routedMedName>
		<routedGenericName>vemurafenib oral</routedGenericName>
		<etcIds>
			<etc_id>5910</etc_id>
		</etcIds>
		<medIds>
			<medId>565766</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Malignant Melanoma with BRAF V600E Mutation</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.14083</icd9>
			<symbolic>Zelboraf-MM</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype_name>
				<name></name>
			</subtype_name>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Hematology &amp; Oncology</name>
					<code>207RH0003X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Pregnancy</name>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name></subtype_name>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
				<comorbidity>
					<name>Breast Feeding</name>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
				<comorbidity>
					<name>QTc interval on ECG is 500 milliseconds or less</name>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion/>
		  <concurrentTherapyExclusion/>
			<dosing>
				<text>960 mg taken twice daily.</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>565766</medId>
					<initPerDayDesc>8 tablets per Day</initPerDayDesc>
					<initPerIntervalDesc>240 tablets per Day</initPerIntervalDesc>
					<renewPerDayDesc>8 tablets per Day</renewPerDayDesc>
					<renewPerIntervalDesc>240 tablets per Day</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Zelboraf (vemurafenib) tablet, oral. Physician Prescribing Information [Internet] Genentech, Inc. 2013 Jul Accessed at: http://www.zelboraf.com/. [created 2011; accessed 2013 Dec 2]</reference>
				<reference>Bollag G, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews. Drug Discovery 2012;11(11):873-86. DOI: 10.1038/nrd3847.</reference>
				<reference>Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncology 2013;14(2):e60-9. DOI: 10.1016/S1470-2045(12)70539-9. </reference>
				<reference>Jordan EJ, Kelly CM. Vemurafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy 2012;13(17):2533-43. DOI: 10.1517/14656566.2012.737780.</reference>
				<reference>Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. NICE Technology Appraisal TA269 [Internet] National Institute for Health and Clinical Excellence. 2012 Dec Accessed at: http://guidance.nice.org.uk/. [accessed 2013 Oct 3] </reference>
				<reference>Melanoma. NCCN Clinical Practice Guidelines in Oncology [Internet] National Comprehensive Cancer Network (NCCN). v 2.2014; 2013 Sep Accessed at: www.nccn.org/professionals/physician_gls/f_guidelines.asp.</reference>
				<reference>Garbe C, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. European Journal of Cancer 2012;48(15):2375-90. DOI: 10.1016/j.ejca.2012.06.013.</reference>
				<reference>Keating GM. Vemurafenib: in unresectable or metastatic melanoma. BioDrugs 2012;26(5):325-34. DOI: 10.2165/11209860-000000000-00000. </reference>
				<reference>Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine 2011;364(26):2507-16. DOI: 10.1056/NEJMoa1103782.</reference>
				<reference>Sosman JA, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine 2012;366(8):707-14. DOI: 10.1056/NEJMoa1112302. </reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives/>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
	</lists>
</paload>
